City Of London Investment Group Plc Insider of Aberdeen Emerging Markets Equit (NYSEAMERICAN:AEF) Just Purchased Shares In It; 4 Analysts Are Bullish Lexicon Pharmaceuticals, Inc. (LXRX) Last Week

May 25, 2018 - By Ash

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Logo

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Ratings Coverage

Among 9 analysts covering Lexicon Pharmaceuticals (NASDAQ:LXRX), 4 have Buy rating, 2 Sell and 3 Hold. Therefore 44% are positive. Lexicon Pharmaceuticals had 25 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has “Buy” rating given on Monday, May 7 by Wedbush. The rating was downgraded by JP Morgan on Monday, August 10 to “Overweight”. Gabelli upgraded the stock to “Hold” rating in Monday, September 28 report. On Tuesday, May 22 the stock rating was maintained by Wedbush with “Buy”. The stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has “Outperform” rating given on Friday, August 5 by Wedbush. The firm earned “Hold” rating on Friday, February 23 by Needham. Cowen & Co maintained Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) on Tuesday, August 1 with “Hold” rating. JP Morgan downgraded the stock to “Underweight” rating in Wednesday, February 14 report. The stock has “Buy” rating by Wedbush on Monday, March 12. On Friday, September 8 the stock rating was maintained by Stifel Nicolaus with “Buy”. See Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) latest ratings:

22/05/2018 Broker: Wedbush Rating: Buy New Target: $42.0000 Maintain
07/05/2018 Broker: Wedbush Rating: Buy New Target: $40.0000 Maintain
04/05/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $28 New Target: $27 Maintain
04/05/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $25 New Target: $24 Maintain
16/04/2018 Broker: Wedbush Old Rating: Outperform New Rating: Outperform Old Target: $38 New Target: $40 Maintain
12/03/2018 Broker: Wedbush Rating: Buy New Target: $38.0 Maintain
23/02/2018 Broker: Needham Rating: Hold Downgrade
14/02/2018 Broker: J.P. Morgan Rating: Sell New Target: $10.0 Downgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade
30/11/2017 Broker: Wedbush Rating: Buy New Target: $38.0 Maintain

The stock decreased 1.67% or $0.16 during the last trading session, reaching $9.41. About 490,189 shares traded. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has declined 43.19% since May 25, 2017 and is downtrending. It has underperformed by 54.74% the S&P500.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company has market cap of $995.88 million. The firm offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults. It currently has negative earnings. The Company’s orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain.

More notable recent Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) news were published by: Globenewswire.com which released: “Lexicon Pharmaceuticals to Present at Upcoming Investor Conference” on May 24, 2018, also Seekingalpha.com with their article: “Biotech Forum: The Week Ahead” published on May 07, 2018, Seekingalpha.com published: “Lexicon Pharmaceuticals Still Has Much To Prove” on May 04, 2018. More interesting news about Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) were released by: Streetinsider.com and their article: “Lexicon Pharma (LXRX), Sanofi (SNY) Announce FDA to Review Zynquista as Potential Treatment for Type 1 Diabetes” published on May 22, 2018 as well as Seekingalpha.com‘s news article titled: “Lexicon Pharmaceuticals’ (LXRX) CEO Lonnel Coats on Q1 2018 Results – Earnings Call Transcript” with publication date: May 03, 2018.

Investors sentiment decreased to 0.77 in Q4 2017. Its down 0.56, from 1.33 in 2017Q3. It worsened, as 5 investors sold Aberdeen Emerging Markets Equit shares while 8 reduced holdings. 6 funds opened positions while 4 raised stakes. 3.06 million shares or 11.23% more from 2.75 million shares in 2017Q3 were reported. James Inv has invested 0.03% in Aberdeen Emerging Markets Equit (NYSEAMERICAN:AEF). Credit Suisse Ag holds 75,000 shares. Pnc Financial Gp Incorporated Inc has 9,052 shares for 0% of their portfolio. Cornerstone invested in 82,214 shares or 0.08% of the stock. Advisory Networks Limited Liability Corp holds 0.01% of its portfolio in Aberdeen Emerging Markets Equit (NYSEAMERICAN:AEF) for 17,701 shares. The New York-based Karpus has invested 0.12% in Aberdeen Emerging Markets Equit (NYSEAMERICAN:AEF). Thomas J Herzfeld Advsrs Incorporated has 0.04% invested in Aberdeen Emerging Markets Equit (NYSEAMERICAN:AEF) for 10,859 shares. The Illinois-based North Star has invested 0% in Aberdeen Emerging Markets Equit (NYSEAMERICAN:AEF). Live Your Vision Llc reported 3,350 shares. City Of London Mngmt Ltd has 367,229 shares for 0.23% of their portfolio. Morgan Stanley owns 15,558 shares. Wolverine Asset Mngmt Lc owns 0% invested in Aberdeen Emerging Markets Equit (NYSEAMERICAN:AEF) for 48,185 shares. Bulldog Investors Ltd Llc owns 2.9% invested in Aberdeen Emerging Markets Equit (NYSEAMERICAN:AEF) for 1.20 million shares. Weiss Asset Mgmt L P, a Massachusetts-based fund reported 159,595 shares. Moreover, Bank Of America De has 0% invested in Aberdeen Emerging Markets Equit (NYSEAMERICAN:AEF) for 4,166 shares.

Aberdeen Emerging Markets Equity Income Fund Inc’s company insider, City Of London Investment Group Plc purchased a total of 25,600 shares of the company, based on a market stock price of $8.7 per share. City Of London Investment Group Plc right now owns 11.80 million shares which are equivalent to around 13.27% of the Pennsylvania-based company’s market capitalization (total value of the shares outstanding). The deal was unveiled in a SEC Form 4 on 24/05/2018.

The stock decreased 0.69% or $0.06 during the last trading session, reaching $8.68. About 143,020 shares traded. Aberdeen Emerging Markets Equit (NYSEAMERICAN:AEF) has 0.00% since May 25, 2017 and is . It has underperformed by 11.55% the S&P500.

Since May 7, 2018, it had 3 insider purchases, and 4 sales for $389,377 activity. CITY OF LONDON INVESTMENT GROUP PLC bought 223,600 shares worth $1.98M.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>